Medicines Australia would like to acknowledge the great contribution made by Dr Anna Lavelle to Australia’s biotechnology industry as she steps down from being the CEO of AusBiotech.
Throughout her eleven years at the helm, Dr Lavelle has been a tremendous advocate for her members and the broader life science sector.
Medicines Australia has had a strong relationship with Dr Lavelle throughout her tenure and worked closely on many issues which affect the biopharmaceutical industry.
Her decision to step away will be a big loss not just to her members but the broader sector as a whole.
A strong biotechnology sector in Australia means a stronger pharmaceutical sector too.
Together, the members of AusBiotech and Medicines Australia play a critical role in the discovery and development of the latest generation in biopharmaceuticals and vaccines which help to improve the lives of millions of Australians.
Medicines Australia wishes Dr Lavelle all the best for her next career phase and we look forward to working with her in any future capacity.
We also look forward to working closely and constructively with the new CEO Glenn Cross. Mr Cross has also had a long career at AusBiotech working alongside Dr Lavelle and is a worthy replacement who will continue to represent the biotechnology industry in the best interests of AusBiotech members.
Phone: 0423 239 265